Why Melanoma and NSCLC Lead the mRNA Vaccine Field

Melanoma and NSCLC dominate the personalized mRNA cancer vaccine patent landscape because both tumors carry the biological properties that make neoantigen-based immunotherapy tractable: high somatic mutational burden, established clinical infrastructure for checkpoint inhibitor combination, and documented immune editing that creates rationale for active immunisation. Patent filings across multiple jurisdictions consistently nominate these two indications as the primary oncology targets for mRNA vaccination strategies.

Melanoma’s patent record is characterised by layered immune-evasion biology. A Stanford University filing specifically identifies ENPP3 as a cGAMP hydrolase that degrades the STING ligand cGAMP, suppressing innate immune signalling in the tumor microenvironment. High ENPP3 mRNA expression stratifies melanoma patients into a subgroup with only a 15.9% 27-year survival probability, compared with 40.3% in low-ENPP3 tumors — a gap that underscores the mechanistic case for immune activation strategies including mRNA vaccination. Separately, biomarker filings from Icahn School of Medicine at Mount Sinai address recurrence risk using CD2, KLRK1, ITK, and HLAE gene expression panels, while the University of Utah Research Foundation has filed patents covering single-cell RNA sequencing (scRNA-seq) and transcriptome-based stratification to predict immune checkpoint inhibitor (ICI) response in melanoma subtypes including acral melanoma.

NSCLC appears as a secondary but significant indication. TRON (Translationale Onkologie, University of Mainz) — the academic affiliate historically associated with BioNTech’s RNA therapeutic programs — has filed directly on RNA therapies for NSCLC, articulating objectives including tumor size reduction, time-to-progression extension, and metastasis prevention. BioNTech SE has separately filed patent claims directed at RNA therapeutics encoding lung cancer tumor-associated antigens including claudin 6 (CLDN6), Kita-Kyushu lung cancer antigen 1 (KK-LC-1), MAGE-A3, MAGE-A4, and PRAME. As WHO data confirms, lung cancer remains the leading cause of cancer mortality globally, making NSCLC a commercially critical indication for any immunotherapy platform seeking broad oncology application.

Five Distinct mRNA Vaccine Architectures Competing for Dominance

The mRNA cancer vaccine patent landscape is not monolithic: at least five technically distinct vaccine architectures have attracted independent commercial IP investment, each with different manufacturing profiles, antigen targeting strategies, and combination rationales. Understanding the differences between these modalities is essential for freedom-to-operate analysis and competitive positioning.

1. Personalized Poly-Neoepitope LNP-mRNA (V940 Architecture)

ModernaTX holds the most extensive patent estate in this dataset on the concatemeric, poly-neoepitope mRNA construct delivered via lipid nanoparticle (LNP). Filed across the US, Canada, Japan, Singapore, and Korea, these patents cover constructs encoding 1–500 personalized cancer antigen peptide epitopes alongside universal Type II T cell epitopes (such as tetanus toxoid and diphtheria toxin sequences) on a single mRNA backbone. Some configurations encode 45–55 epitopes per construct. The V940 program — developed jointly by Moderna and Merck — corresponds to this architecture: patent records describe constructs encoding up to 34 patient-specific tumor neoantigens administered intramuscularly every 3 weeks for up to 9 doses, in combination with pembrolizumab (200 mg IV every 3 weeks for up to 18 cycles) in resected high-risk cutaneous melanoma (stages IIIB–IV).

2. Shared TAA mRNA Vaccines — BNT111 Platform

BioNTech SE’s patent activity describes RNA therapeutic compositions targeting fixed tumor-associated antigens for NSCLC and related cancers, including CLDN6, KK-LC-1, MAGE-A3, MAGE-A4, and PRAME. Unlike purely personalized neoantigen vaccines, this approach encodes shared antigens expressed by a definable patient subset, enabling manufacturing with the biological precision of RNA encoding but without the per-patient turnaround time of individualized construct design. This architecture is consistent with the BNT111 program targeting shared melanoma-associated antigens. TRON’s associated filings on RNA therapy for NSCLC reinforce this approach, describing intent to reduce tumor size, inhibit metastasis, and extend survival.

3. Computational/ML-Based Neoantigen Identification Platforms

Gritstone Bio (formerly Gritstone Oncology) occupies a distinct niche: rather than filing on vaccine formulations per se, its patent portfolio covers the computational and experimental infrastructure for neoantigen identification. Patents describe machine-learned MHC presentation models that accept tumor-sequencing-derived peptide sequences and generate per-allele presentation likelihood scores, enabling selection of high-confidence neoepitopes for inclusion in therapeutic vaccines. The methodology encompasses pan-allele models and hotspot-based neoantigen identification, and extends to T cell therapy via TCR sequencing and adoptive transfer. As research published via Nature has increasingly shown, accurate MHC presentation prediction is foundational to vaccine efficacy — making Gritstone’s platform patents a potential licensing leverage point for any organisation developing personalised mRNA vaccines.

4. Co-Stimulatory mRNA Encoding (Intranodal — Etherna)

Etherna Immunotherapies NV has filed on a distinct combination mRNA modality: co-encoding of CD40, constitutively active TLR4 (caTLR4), and CD70 as immune-activating signals within the same mRNA therapeutic product alongside tumor-associated antigen-encoding mRNAs, administered via intranodal injection. Retrieved filings describe this approach specifically for stable malignant melanoma, with the patient population described as metastatic cancer patients primarily with stable disease or partial response to prior therapy — indicating a clinical-stage design rationale.

5. RNA Vaccine + PD-1 Axis Combination Methods (Genentech/Roche)

Genentech, Inc. has a substantial filing footprint covering methods for treating cancer — including melanoma and urothelial carcinoma — by co-administering personalized RNA vaccines encoding tumor-specific neoepitopes with PD-1 axis binding antagonists, sometimes alongside chemotherapy. A related F. Hoffmann-La Roche AG filing describes methods for inducing neoepitope-specific CD8+ T cell trafficking to tumors via RNA vaccine plus PD-1 axis blockade combinations, specifying that at least approximately 1% of circulating CD8+ T cells should be reactive to vaccine-encoded neoepitopes as a response benchmark — a clinically actionable pharmacodynamic endpoint.

“ModernaTX holds a multi-jurisdictional patent estate covering the poly-neoepitope LNP-mRNA architecture, universal T cell epitope co-encoding, STING integration, and oncogenic mutation peptide co-encoding — creating layered IP that competitors seeking to develop analogous constructs must design around.”

Key Molecular Targets: From Neoantigens to ENPP3

The molecular target landscape for personalized mRNA cancer vaccines spans three tiers: patient-specific neoepitopes derived from somatic mutations, shared tumor-associated antigens expressed across patient subsets, and immunostimulatory pathway components co-encoded to enhance innate-adaptive immune crosstalk. Each tier is represented by distinct patent families with different IP ownership profiles.

Patient-Specific Neoepitopes

The central therapeutic target across retrieved results is the individualized neoepitope — peptide sequences arising uniquely from cancer-specific somatic mutations. ModernaTX’s poly-neoepitope mRNA constructs encode 45–55 epitopes per construct in some configurations, with personalized cancer antigens selected from patient-specific tumor sequencing. Genentech filings describe RNA vaccine-encoded neoepitopes as the driver of de novo significantly expanded (SE) TCR clones, positing that the number and frequency of these clones may serve as a predictive biomarker for vaccine response. Standards bodies including ISO are increasingly developing frameworks for the analytical validation of tumor sequencing assays that underpin neoantigen identification — a regulatory consideration for companion diagnostic development.

Shared Tumor-Associated Antigens (CLDN6, MAGE-A3/A4, PRAME, KK-LC-1)

BioNTech SE’s NSCLC-directed RNA therapeutic explicitly targets CLDN6, MAGE-A3, MAGE-A4, PRAME, and KK-LC-1 as tumor-associated antigens with immunogenic fragments deliverable via RNA. PRAME is also noted in Myriad Genetics’ melanoma biomarker context as a diagnostic and therapeutic target. These shared antigens offer a manufacturing advantage over fully individualized vaccines: construct design can be completed before patient enrollment, compressing the time from biopsy to treatment initiation.

STING Pathway and KRAS/p53 Co-Encoding

ModernaTX filings consistently note the incorporation of STING-encoding sequences within poly-neoepitope mRNA constructs as a means of generating innate immune co-stimulation alongside adaptive neoantigen-specific responses. The same filings identify KRAS and p53 mutations as activated oncogene mutation peptides that can be co-encoded on the same mRNA construct alongside personalized neoantigens — enabling targeting of recurrent driver mutations shared across patients while preserving the personalized neoepitope payload. This dual-targeting approach represents an evolution toward constructs with both individualized and population-level antigen coverage.

Who Holds the Patents: Assignee Landscape and IP Concentration

Patent activity in the mRNA cancer vaccine space is strongly concentrated among a small number of commercial and academic assignees, with activity overwhelmingly patent-driven — consistent with an active commercial IP landscape surrounding mRNA cancer vaccine manufacturing, formulation, and clinical method claims. Understanding the IP ownership map is essential before any R&D or business development decision in this space.

ModernaTX, Inc. (Moderna) is the most represented assignee for personalized mRNA cancer vaccine patents, filing across the US, Canada, Japan, Singapore, and Korea. Its poly-neoepitope LNP-mRNA architecture underpins the V940 program and is protected by a broad family of concatemeric mRNA cancer vaccine patents filed from 2017 onward, with active cases still pending as of 2025.

Genentech, Inc. / F. Hoffmann-La Roche AG is the most active assignee for RNA vaccine + PD-1 axis combination method patents, filing across the US, Canada, Mexico, Australia, Taiwan, Japan, and China. Their filings address cancer-agnostic personalized RNA vaccine methods with specific clinical designs including pancreatic cancer, urothelial carcinoma, and general solid tumor indications. The breadth of these method claims across jurisdictions creates a significant freedom-to-operate consideration for any organisation combining personalized RNA vaccines with anti-PD-1/L1 agents.

TRON / BioNTech SE drive the NSCLC-specific and shared-TAA RNA therapeutic patent activity. TRON filings describe RNA therapy directly for NSCLC; BioNTech SE’s filings cover specific TAA combinations including CLDN6, MAGE-A3/A4, PRAME, and KK-LC-1. Gritstone Bio, Inc. holds the dominant position in neoantigen identification platform patents, covering machine-learned MHC presentation models, pan-allele approaches, hotspot-based selection, and neoantigen-specific T cell identification for adoptive therapy. Etherna Immunotherapies NV represents a European biotech approach with patents on intranodal TAA mRNA vaccine plus co-stimulatory mRNA combinations specifically for metastatic melanoma.

Merck Sharp & Dohme LLC is the dominant assignee for biomarker patents relevant to patient selection for PD-1 antagonist + RNA vaccine combination approaches, covering gene expression signatures predictive of melanoma patient outcomes and blood-based biomarkers of PD-1 antagonist sensitivity. Academic institutions — including Stanford University, University of Utah Research Foundation, Icahn School of Medicine at Mount Sinai, and University of California — contribute patents primarily to melanoma patient stratification and immune contexture characterisation methodologies. According to WIPO, biopharmaceutical patent filings in oncology immunotherapy have grown substantially over the past decade, with RNA therapeutics representing one of the fastest-growing sub-categories.

Combination Strategies and Emerging Directions

The most consistently represented combination strategy across the retrieved dataset is personalized RNA vaccine co-administered with a PD-1 or PD-L1 axis antagonist. Multiple independent assignees — including ModernaTX/Merck, Genentech/Roche, and BioNTech — have independently filed on this approach across different tumor types, signalling broad industry consensus around this combination rationale. Beyond checkpoint blockade, several emerging directions are visible in the patent record.

RNA Vaccine + Chemotherapy (Tripartite Regimens)

Genentech filings extend the combination to tripartite regimens: individualized RNA vaccine + PD-1 axis antagonist + chemotherapy, primarily for pancreatic cancer but with method claims broad enough to encompass other solid tumors. This reflects a broader oncology strategy of layering immunogenic cell death induced by chemotherapy with the adaptive immune priming of neoantigen vaccination.

STING Agonist Co-Encoding

ModernaTX signals suggest that mRNA constructs encoding STING pathway activators alongside neoepitopes may enhance innate-adaptive immune co-stimulation, representing an evolution of the poly-neoepitope construct toward built-in adjuvanticity. This approach would eliminate the need for a separate adjuvant formulation — a manufacturing and regulatory simplification with commercial implications.

ENPP3 Inhibition + PD-1 Blockade

Stanford’s discovery of ENPP3 as a cGAMP hydrolase that suppresses STING signalling in the tumor microenvironment suggests a potential combination strategy: ENPP3 inhibitor + PD-1 blockade (and potentially + RNA vaccination) in ENPP3-high melanoma patient subsets. Given the 24.4 percentage point survival gap between ENPP3-high and ENPP3-low melanoma patients, this patient-stratified combination approach has significant clinical and commercial rationale.

OX40L/IL-12/IL-15 mRNA Combinations

A Moderna filing describes mRNA therapeutics encoding OX40L, IL-12, and IL-15 in LNP formulations for intratumoral or intravenous use, indicating exploration of cytokine-co-stimulatory mRNA approaches that could be layered onto vaccine regimens. This signals a potential evolution toward multi-component mRNA immunotherapy products that combine antigen delivery with cytokine microenvironment remodelling in a single therapeutic.

Strategic Implications for IP and R&D Teams

The patent signals in this dataset translate into concrete strategic considerations for IP counsel, R&D leaders, and business development teams operating in the mRNA cancer vaccine space. Five implications stand out from the landscape analysis.

V940 represents the leading clinical signal for personalized mRNA vaccination in melanoma. ModernaTX’s multi-jurisdictional patent estate covers the poly-neoepitope LNP-mRNA architecture, universal T cell epitope co-encoding, STING integration, and oncogenic mutation (KRAS/p53) peptide co-encoding. The layered nature of this IP creates a design-around burden for any organisation seeking to develop analogous constructs — particularly given active cases still pending as of 2025.

BioNTech/TRON hold differentiated IP for shared TAA-based RNA therapeutics in NSCLC, targeting CLDN6, MAGE-A3/A4, PRAME, and KK-LC-1. This approach competes on manufacturing speed and scalability versus the turnaround-time challenge of fully individualized vaccines like V940. IP strategists should note this is a technically and commercially distinct strategy — not merely a simpler version of the personalized approach.

Gritstone Bio’s computational neoantigen selection platform patents represent a potential licensing or partnership leverage point for any organisation developing personalized mRNA vaccines. Machine-learned MHC presentation likelihood models that improve neoepitope selection quality are foundational enablers of vaccine efficacy — and Gritstone’s patents cover both the models and the experimental validation infrastructure.

Genentech/Roche’s method claims on RNA vaccine + PD-1 axis antagonist combination treatment cover broad cancer types and are active across multiple jurisdictions. Organisations intending to combine personalized RNA vaccines with anti-PD-1/L1 agents should conduct freedom-to-operate analysis against Genentech’s pending and active family before advancing clinical programs. The European Patent Office and USPTO both have active examination proceedings in this area.

Patient stratification biomarkers are emerging as co-development necessities. Biomarkers including tumor mutational burden (TMB), ENPP3 expression, gene expression signatures (angiogenesis, mMDSC), and TCR clonal expansion are represented across filings from Merck, Roche/Foundation Medicine, Stanford, and University of California. These biomarker IP holdings could define companion diagnostic requirements for regulatory submissions and reimbursement decisions — making early freedom-to-operate analysis in the biomarker space as important as the vaccine construct itself.

“Patient stratification biomarkers — including TMB, ENPP3 expression, gene expression signatures, and TCR clonal expansion — are emerging as co-development necessities for personalized mRNA vaccine programs, with IP held across Merck, Roche/Foundation Medicine, Stanford, and University of California.”